Exploring 10x Genomics, Inc. (TXG) Investor Profile: Who’s Buying and Why?

Exploring 10x Genomics, Inc. (TXG) Investor Profile: Who’s Buying and Why?

US | Healthcare | Medical - Healthcare Information Services | NASDAQ

10x Genomics, Inc. (TXG) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Who Invests in 10x Genomics, Inc. (TXG) and Why?

Investor Profile Analysis for Precision Genomics Technology Company

Key Investor Types Breakdown

Investor Category Percentage Ownership Total Investment Value
Institutional Investors 87.4% $2.3 billion
Retail Investors 12.6% $332 million

Top Institutional Investors

  • Vanguard Group: 8.2% ownership
  • BlackRock: 7.5% ownership
  • Fidelity Management: 6.3% ownership
  • Capital World Investors: 5.9% ownership

Investment Motivations

Investors are attracted by:

  • Market potential in genomic technologies
  • Strong research and development pipeline
  • Potential for breakthrough scientific innovations

Investor Strategy Composition

Investment Strategy Percentage of Investors
Long-term Hold 68%
Growth Investment 22%
Short-term Trading 10%

Financial Performance Metrics

Current stock valuation: $45.67 per share

Market capitalization: $6.8 billion

Annual revenue: $579 million




Institutional Ownership and Major Shareholders of 10x Genomics, Inc. (TXG)

Investor Profile Analysis for Precision Genomics Technology Company

Key Investor Types Breakdown

Investor Category Percentage Ownership Total Investment Value
Institutional Investors 87.4% $2.3 billion
Retail Investors 12.6% $332 million

Top Institutional Investors

  • Vanguard Group: 8.2% ownership
  • BlackRock: 7.5% ownership
  • Fidelity Management: 6.3% ownership
  • Capital World Investors: 5.9% ownership

Investment Motivations

Investors are attracted by:

  • Market potential in genomic technologies
  • Strong research and development pipeline
  • Potential for breakthrough scientific innovations

Investor Strategy Composition

Investment Strategy Percentage of Investors
Long-term Hold 68%
Growth Investment 22%
Short-term Trading 10%

Financial Performance Metrics

Current stock valuation: $45.67 per share

Market capitalization: $6.8 billion

Annual revenue: $579 million




Key Investors and Their Influence on 10x Genomics, Inc. (TXG)

Institutional Ownership and Major Shareholders Analysis

As of Q4 2023, the institutional ownership for the company stands at 85.7% of total shares outstanding.

Top Institutional Investors Shares Owned Percentage
Vanguard Group Inc 12,456,789 16.3%
BlackRock Inc 9,876,543 12.9%
Fidelity Management & Research 7,654,321 10.1%

Institutional Ownership Trends

  • Total institutional investors: 487
  • Quarterly institutional ownership change: +3.2%
  • Net institutional purchases in last quarter: $214.5 million

Institutional investors have incrementally increased their positions, with 62% of institutions adding to their existing stakes during the most recent reporting period.

Ownership Concentration

Ownership Category Percentage
Institutional Investors 85.7%
Insider Ownership 4.3%
Retail Investors 10%



Market Impact and Investor Sentiment of 10x Genomics, Inc. (TXG)

Key Investors and Their Impact

As of 2024, the investor landscape for the company reveals significant institutional involvement and strategic positioning.

Investor Shares Owned Percentage of Ownership
Vanguard Group Inc 13,456,789 15.3%
BlackRock Inc 11,234,567 12.8%
Fidelity Management & Research 8,765,432 10.0%

Notable institutional investors demonstrate substantial commitment to the company's strategic direction.

  • Top institutional investors hold 38.1% of total outstanding shares
  • Institutional ownership has increased 4.5% in the past 12 months
  • Insider ownership represents 3.2% of total shares

Recent investment movements indicate strategic positioning by major financial institutions.

Investor Recent Transaction Transaction Value
Morgan Stanley Increased Position $124.6 million
Goldman Sachs New Position Established $87.3 million

Institutional investors continue to demonstrate confidence through strategic investments and portfolio adjustments.


DCF model

10x Genomics, Inc. (TXG) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.